Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 6

Evaluation of treatment results and access to health support of malignant pleural mesothelioma patients in Cappadocia

Pages
1771–1775
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients' overall survival (OS), progression-free survival (PFS) and accessto health support were examined.Results: The median follow-up period was 26 (range 1-153) months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Malignant Pleural Mesothelioma (MPM) is frequently observed due to erionite in Cappadocia.
📊
Key Findings & Data:In this study, patients who live inCappadocia region and were treated in Nevsehir State Hospital were evaluated.Material Method: In this study, the data of 22 patients admitted to Nevşehir State Hospital and diagnosed with MPM between15.7.2009-27.08.19 were evaluated retrospectively.
💡
Conclusion & Impact:The patients' overall survival (OS), progression-free survival (PFS) and accessto health support were examined.Results: The median follow-up period was 26 (range 1-153) months.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Malignant Pleural Mesothelioma (MPM) is frequently observed due to erionite in Cappadocia. In this study, patients who live inCappadocia region and were treated in Nevsehir State Hospital were evaluated.Material Method: In this study, the data of 22 patients admitted to Nevşehir State Hospital and diagnosed with MPM between15.7.2009-27.08.19 were evaluated retrospectively. The patients' overall survival (OS), progression-free survival (PFS) and accessto health support were examined.Results: The median follow-up period was 26 (range 1-153) months. The median age of the patients at the time of diagnosis was 65years (range 36-86). Only 2 (9.1%) patients were localized / operable at the time of diagnosis; three patients (13.6%) were metastaticand 17 (77.3%) were in-operable. The female / male ratio of our patients was 1/1. The 3 patients (13.6%) were diagnosed at NevşehirState Hospital, and 19 patients (86.4%) were diagnosed outside the Cappadocia. During the follow-up period, 19 patients (86.4%)deceased and 3 patients (13.6%) were alive. The median OS of the patients was 19 (range 1-133) months. The relapse was observedin 19 patients (86.4%). The median PFS value is 10 (range 1-126) months.Conclusion: There is not enough infrastructure in Cappadocia in terms of diagnosis and treatment of MPM. The people of Cappadocianeed to be supported in terms of access to MPM treatment. The OS of MPM has not improved significantly over the past 40 years.

🔖

Cite This Article

ARAL, İ. P. (2022). Evaluation of treatment results and access to health support of malignant pleural mesothelioma patients in Cappadocia. Annals of Medical Research, Cilt: 27 - Sayı: 6, 1771–1775. https://ajindex.com/articles/446201

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hiriart E, Deepe R, Wessels A. Mesothelium and Malignant Mesothelioma. J Dev Biol 2019;7:7
  2. Taioli E, Wolf AS, Camocho- Rivera M, et al. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. PloS one 2015;10:0145039
  3. Petrelli F, Ardito R, Conti B, et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respiratory Med 2018;141:72-80
  4. Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 2016;25:472-86
  5. Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Eur Respir Rev 2016;25:472-86
  6. Taioli E, Wolf AS, Camacho-Rivera M, et al. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg 2014;98:1020-4
  7. Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary Treatment of Malignant Pleural Mesothelioma. The Oncologist 2007;12:850-63
  8. Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet 2018;19:161-72 9. Tsao AS, Lindwasswer O, Adjei AA, et al. Current and Future Managament of Malignant Mesothelioma: A consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee,International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation. J Thorasic Oncology 2018;13:1655-7
  9. Amin W, Linkov F, Landsittel DP. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank Cohort. F1000 Res 2018;7:1184
  10. Koyuncu A, Koksal D, Ozmen O, et al. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients. J Cancer Res Ther 2015; 11:216-22
  11. Kindler HL, Ismaila N, Armato SG, et al.Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Practice Guidline. J Clinical Oncology 2018; 13:1343-73
  12. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-65
  13. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9
  14. Vogelzang NJ, Rusthoven JJ, Symanowski J,